Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company has collaboration agreement with Novartis to conduct three Phase IIb clinical trials Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-376-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$35.38 million
Profitability
Miscellaneous
Employees33
OptionableOptionable
Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions
What is Conatus Pharmaceuticals' stock symbol?
Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."
How were Conatus Pharmaceuticals' earnings last quarter?
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.15). The biotechnology company earned $7.67 million during the quarter, compared to analysts' expectations of $9.70 million. Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%. View Conatus Pharmaceuticals' Earnings History.
When is Conatus Pharmaceuticals' next earnings date?
What price target have analysts set for CNAT?
5 brokerages have issued 1-year target prices for Conatus Pharmaceuticals' shares. Their forecasts range from $4.00 to $15.00. On average, they expect Conatus Pharmaceuticals' share price to reach $10.25 in the next year. This suggests a possible upside of 442.3% from the stock's current price. View Analyst Price Targets for Conatus Pharmaceuticals.
What is the consensus analysts' recommendation for Conatus Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Conatus Pharmaceuticals.
Has Conatus Pharmaceuticals been receiving favorable news coverage?
News headlines about CNAT stock have been trending positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Conatus Pharmaceuticals earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Conatus Pharmaceuticals' key competitors?
Some companies that are related to Conatus Pharmaceuticals include Savara (SVRA), Kamada (KMDA), Acer Therapeutics (ACER), MannKind (MNKD), Paratek Pharmaceuticals (PRTK), Syros Pharmaceuticals (SYRS), Synlogic (SYBX), LifeVantage (LFVN), resTORbio (TORC), Dova Pharmaceuticals (DOVA), Xeris Pharmaceuticals (XERS), Tocagen (TOCA), Strongbridge Biopharma (SBBP), Galectin Therapeutics (GALT) and Athersys (ATHX).
Who are Conatus Pharmaceuticals' key executives?
Conatus Pharmaceuticals' management team includes the folowing people:
- Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
- Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
- Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
- Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
- Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications
Who are Conatus Pharmaceuticals' major shareholders?
Conatus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.33%), Two Sigma Investments LP (0.83%), Geode Capital Management LLC (0.69%), Hikari Power Ltd (0.55%), Acadian Asset Management LLC (0.51%) and Bank of America Corp DE (0.30%). View Institutional Ownership Trends for Conatus Pharmaceuticals.
Which institutional investors are selling Conatus Pharmaceuticals stock?
Which institutional investors are buying Conatus Pharmaceuticals stock?
How do I buy shares of Conatus Pharmaceuticals?
Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Conatus Pharmaceuticals' stock price today?
One share of CNAT stock can currently be purchased for approximately $1.89.
How big of a company is Conatus Pharmaceuticals?
Conatus Pharmaceuticals has a market capitalization of $57.20 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 33 workers across the globe.
What is Conatus Pharmaceuticals' official website?
How can I contact Conatus Pharmaceuticals?
Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]
MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
